Cynaptec Pharmaceuticals

Cynaptec Pharmaceuticals, Inc.

1 Investors

Biopharmaceuticals

STUART, FL

Cynaptec Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies for neurological and psychiatric disorders. Their primary emphasis lies in addressing significant unmet medical needs, particularly for conditions that currently lack effective treatments.

Products & Team

Conjugated Psilocin™

Neurological TherapySeed

Conjugated Psilocin™ is a patented, oral, and stable analog of psilocin, which is the active metabolite of psilocybin. This compound has been engineered for enhanced stability and bioavailability, making it more suitable for clinical use compared to traditional psilocin formulations.

Value Proposition

Conjugated Psilocin™ offers a new therapeutic option for patients suffering from chronic cluster headaches, an orphan disease with limited treatment efficacy.

Pain Points

Chronic cluster headache sufferers face inadequate treatment options, significantly affecting their quality of life.

Oral administrationIncreased stabilityImproved bioavailabilityPotential therapeutic efficacy in treating neurological and psychiatric disorders